Business Context and Reporting Period
Company: Pluri Inc. (Nasdaq: PLUR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: Pluri is a biotechnology company utilizing a proprietary 3D cell expansion platform for regenerative medicine, immunotherapy, food tech, agtech, and Contract Development and Manufacturing Organization (CDMO) services. The company operates primarily through its Israeli subsidiary, Pluri Biotech Ltd., with additional subsidiaries in Germany and Israel for food and agtech ventures.
Key Financial Metrics
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Revenues | $326,000 | $287,000 |
| Net Loss | $(21,344,000) | $(28,887,000) |
| Loss Per Share (Basic & Diluted) | $(3.99) | $(6.24) |
| Research & Development Expenses (Net) | $(12,446,000) | $(15,745,000) |
| General & Administrative Expenses | $(10,034,000) | $(11,779,000) |
| Cash Used in Operating Activities | $(18,021,000) | $(22,857,000) |
| Cash and Cash Equivalents (End of Period) | $6,783,000 | $5,360,000 |
| Short-term Bank Deposits | $23,202,000 | $34,811,000 |
| Total Current Assets | $31,107,000 | $41,409,000 |
| Total Current Liabilities | $4,454,000 | $5,621,000 |
| Working Capital Surplus | $26,653,000 | $35,788,000 |
| Accumulated Deficit | $(420,472,000) | $(399,584,000) |
| Long-term Debt (EIB Loan) | $24,027,000 | $23,530,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14% to $326,000, driven by the launch of the PluriCDMO business and a proof-of-concept (POC) collaboration in agtech.
- Expense Reduction: Net loss decreased by 26% to $21.3 million. R&D expenses dropped 21% due to the completion of several clinical studies (CLI, COVID-19, muscle regeneration) and a reduction of 16 R&D employees. G&A expenses decreased 15% due to reduced share-based compensation and executive salary reductions.
- Financial Income: Total financial income turned positive ($814,000) compared to a net expense of $1.6 million in the prior year, primarily due to favorable exchange rate differences on the Euro-denominated EIB loan and increased interest income.
- Share Capital: A 1-for-8 reverse stock split was effected on April 1, 2024. As of September 13, 2024, there were 5,470,163 shares outstanding.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Liquidity: Management believes current resources are sufficient to fund operations for at least the next twelve months.
- Revenue Expectations: The company does not expect to generate significant revenues from product sales in the next twelve months. Future revenue is expected from CDMO services, collaborations, and licensing.
- Profitability: The company expects to continue incurring losses in the short term as it advances R&D and commercial operations.
Key Risks and Contingencies
- Nasdaq Compliance: On May 28, 2024, the company received a deficiency letter for failing to meet the $2.5 million shareholders' equity requirement. A compliance plan was submitted, granting an extension until November 24, 2024. Failure to comply may result in delisting.
- Geopolitical Risk: Operations are centered in Israel. Ongoing conflict with Hamas and Hezbollah poses risks to business continuity, employee availability (reserve duty), and supply chains.
- Capital Requirements: The company has a history of losses and an accumulated deficit of $420.5 million. It may need to raise additional capital, which could result in shareholder dilution.
- Regulatory Approvals: Success depends on obtaining regulatory approvals for cell therapy candidates (PLX-PAD, PLX-R18, MAIT cells) and cultivated food products, which is uncertain and costly.
Unusual Items
- Executive Compensation Adjustments: In response to the conflict in Israel, the CEO and CFO voluntarily accepted a 20% salary reduction for specific months in late 2023 and early 2024.
- Ever After Foods Funding: In June 2024, the cultivated meat joint venture, Ever After Foods, raised $10 million in a private placement. Pluri invested $1.25 million, maintaining a 69% ownership stake.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify if the company has met the shareholders' equity requirement by the November 24, 2024 deadline to avoid delisting.
- Cash Burn Rate: Monitor the rate of cash consumption against the $30.9 million total liquid assets (cash, equivalents, and deposits) to assess runway.
- CDMO Revenue Trajectory: Confirm if the new CDMO division is generating recurring revenue sufficient to offset operating costs.
- Geopolitical Impact: Assess any operational disruptions or delays in clinical trials resulting from the ongoing conflict in Israel.
- Grant Funding: Verify the status of non-dilutive funding from the NIAID ($4.2M contract) and EU Horizon programs, which offset R&D expenses.